How Sharma was paid
$763,750 in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Options | Other | Total |
|---|---|---|---|---|---|
| Panna SharmaChief Executive Officer and President | $575,000 | $178,250 | — | $10,500 | $763,750 |
| David R. MargraveChief Financial Officer and Secretary | $413,800 | $116,480 | $44,800 | $10,500 | $585,580 |
| Kishor Bhatia, Ph.D.Chief Scientific Officer | $189,600 | $26,736 | $22,400 | $5,688 | $244,424 |
What changed and why
- $764K$763,750: CEO total compensation in 2025, down from $1,090,634 in 2024.
- $178K$178,250: CEO bonus in 2025, down from $281,750 in 2024.
- $44,800$44,800 and $22,400: option awards for the CFO and Chief Scientific Officer, respectively; CEO received none.
- $20,000$20,000 and $10,000 options: 2025 grants to the CFO and Chief Scientific Officer, vesting monthly over 24 months.
- $5.04$5.04 per share: repriced exercise price for eligible options held by all three named executives.
- Bonuses were tied to operational and strategic milestones, with awards determined under executive agreements.
Other Lantern Pharma proxy statements
- 2025 proxy statement
Panna Sharma paid $1.1M (+59% on the year).
Filed Aug 08, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.